top of page
S379_CD45RO FOXP3 40x_2Snapshot1.tif

Don't stop there!

Icone collegamenti_Tavola disegno 1 copia 45.png

​Check out our press releases and keep up to date.

Additional Financing for Lever Bio: the Oncology Start-up Extends its Seed Round to €9M

  • Immagine del redattore: Lever Bio
    Lever Bio
  • 22 dic 2025
  • Tempo di lettura: 2 min

Turin, December 22, 2025 – Lever Bio, a biotech startup founded in early 2025 and focused on the development of immuno-oncology therapies aimed at reprogramming the tumor microenvironment, today announced the extension of its seed round launched in April, bringing total funds raised to over €9 million.


The investment includes an additional commitment from existing investors Claris Ventures and Ora Global, as well as the entry of business angels from Club degli Investitori and Italian Angels for Growth.


The additional capital will enable the company to conduct preclinical toxicology studies on one of its six programs currently in development, with the goal of submitting an application to initiate a clinical trial by the end of 2027.


In parallel, the fundings already raised will continue to support the development of the other assets in the pipeline, leveraging synergies and collaborations among the research groups that contributed to the scientific discoveries underlying the projects (Prof. Massimiliano Mazzone - VIB-KU Leuven; Prof. Giraudo and Prof. Serini - Candiolo Cancer Institute FPO-IRCCS; Prof. Manzo - University of Turin).


“We are thrilled by the trust shown by private investor groups that are becoming increasingly active in the Italian biotech ecosystem, as well as by the renewed support from our initial investors,” commented Dr. Chiara Donini, Head of Scientific Development at Lever Bio. “The development platform established during our first year of operations has already enabled us to nominate a preclinical candidate that we expect to advance shortly into toxicology studies and, over the course of the coming year, should support the identification of up to three additional preclinical candidates across other programs in our pipeline.”

 

Contacts:


Lever Bio

Lever Bio is a biotechnology company focused on the development of next-generation immuno-oncology therapies. By leveraging metabolic and immune system reprogramming, the company aims to overcome resistance mechanisms to existing cancer therapies, particularly in solid tumors. Through strategic in-licensing agreements and collaborations with leading research institutions, Lever Bio is committed to developing novel biologics with the goal of expanding and improving therapeutic options available to patients.


bottom of page